Ownership and insider activity for MAIA Biotechnology, Inc. (MAIA): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
MAIA Biotechnology, Inc. is a clinical-stage biotech firm dedicated to discovering, developing, and commercializing treatments for various cancers, with a primary focus on non-small cell lung cancer. The company's leading experimental compound, THIO, is an investigational drug candidate that utilizes a unique dual mechanism by targeting telomeres and stimulating an immune response. Established in 2018, the enterprise maintains its headquarters in Chicago, Illinois.
Price
| Price | $1.40 |
| Market Cap | $85M |
| Exchange | AMEX |
| Country | US |
Balance Sheet (10y)
| Year | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $1.7M | $663457 | $10.6M | $11.0M | $7.2M | $9.6M | $8.66B |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Receivables | 0 | 0 | $43666 | $302789 | $144680 | $77347 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | $1.7M | $746505 | $10.7M | $11.8M | $7.6M | $10.2M | $9.7M |
| Property, Plant & Equipment | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | $1.7M | $746505 | $11.3M | $12.0M | $7.6M | $10.2M | $9.7M |
| Accounts Payable | $169188 | $154886 | $960401 | $1.2M | $1.6M | $1.5M | $2.0M |
| Short-term Debt | $25000 | $31953 | 0 | 0 | 0 | 0 | 0 |
| Total Current Liabilities | $374565 | $1.7M | $2.1M | $3.3M | $4.9M | $3.8M | $5.8M |
| Long-term Debt | $9172 | $431801 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | $409737 | $2.4M | $2.1M | $3.5M | $7.1M | $6.5M | $7.3M |
| Retained Earnings | -$9.3M | -$15.9M | -$28.4M | -$44.2M | -$64.0M | -$87.2M | -$109.6M |
| Total Equity | -$172867 | -$3.3M | $9.2M | $8.5M | $477511 | $3.6M | $2.4M |
| Total Debt | $34172 | $463754 | 0 | 0 | 0 | 0 | 0 |
| Net Debt | -$1.7M | -$199703 | -$10.6M | -$11.0M | -$7.2M | -$9.6M | -$8.66B |
| Working Capital | $1.4M | -$947239 | $8.5M | $8.5M | $2.6M | $6.3M | $3.9M |
Financial Health
| Debt / Equity | 0.00 |
| Current Ratio | 4.51 |
| Piotroski F-Score | 2 |
| Altman Z-Score | -19.57 |
Profitability
| Return on Equity | -211.15% |
| Return on Invested Capital | -131.68% |
| Return on Assets | -95.06% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ANVS · BCAB · CALC · CELU · ELUT · LTRN · PYPD
Explore sector: Healthcare · Biotechnology
More sections of MAIA: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks